spacer
home > epc > autumn 2003 > new approaches to developing cancer drugs
PUBLICATIONS
European Pharmaceutical Contractor

New Approaches to Developing Cancer Drugs

The latest statistics make alarming reading: in the developed world one in three people will suffer from cancer and one in four will die from the disease. Due to an ageing population the worldwide incidence of cancer is predicted to double from 10 to 20 million by 2020 (WHO). Traditional approaches to cancer treatment rely on a combination of surgery, radiotherapy and chemotherapy. Current cancer drugs, which are mostly lethal for cells (cytotoxic), either affect DNA synthesis and the process of cell division or they react chemically with DNA to cause chromosomal damage.

These drugs have major limitations as they damage all proliferating cells and therefore produce considerable side effects. Drug resistance is another serious problem. Hence there is a major unmet need for more systematic but innovative and effective therapies for cancer treatment, especially for targeting early stages of the disease or later stage metastatic disease.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Gijsbertus J Pronk PhD, Senior Director, US Business Development at atugen AG

Gijsbertus J Pronk, PhD, is Senior Director in charge of US business development for atugen AG, Germany. Bert joined atugen, USA Inc in 2000 as Director of Research having formerly been Senior Scientist for Target Development with Chiron Corporation. Previously he held various research posts including a post-doctoral assignment in the laboratory of Dr Lewis T Williams at the Cardio-Vascular Research Institute (CVRI) at UC-San Francisco, where he studied programmed cell death (apoptosis).

spacer
Gijsbertus J Pronk
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement